 adjuv topic chemotherapi versu immunotherapi primari superfici transit cell carcinoma bladder prospect studi efficaci ethoglucid keyhole-limpet haemocyanin klh recurr tumour transurethr resect primari superfici transit cell carcinoma bladder patient ethoglucid solut weekli week year patient klh mg klh bladder instil mg week monthli year recurr rate disease-fre interv tumour progress rate end-point studi progress stage grade recurr observ period minimum length follow-up year recurr rate mean disease-fre interv progress rate group signific differ